- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Patent holdings for IPC class A61K 35/17
Total number of patents in this class: 11214
10-year publication summary
183
|
422
|
584
|
819
|
1232
|
1514
|
1724
|
1922
|
1450
|
416
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Immatics Biotechnologies GmbH | 1144 |
485 |
The Trustees of the University of Pennsylvania | 4122 |
262 |
The Regents of the University of California | 18943 |
250 |
Memorial Sloan-Kettering Cancer Center | 1789 |
203 |
Iovance Biotherapeutics, Inc. | 301 |
199 |
Board of Regents, The University of Texas System | 5370 |
194 |
Juno Therapeutics, Inc. | 365 |
149 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
137 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
129 |
H. Lee Moffitt Cancer Center and Research Institute, Inc. | 829 |
101 |
City of Hope | 943 |
97 |
Autolus Limited | 232 |
94 |
Cellectis | 397 |
94 |
The General Hospital Corporation | 4517 |
92 |
Baylor College of Medicine | 875 |
92 |
Novartis AG | 11238 |
89 |
Kite Pharma, Inc. | 315 |
85 |
Fred Hutchinson Cancer Center | 376 |
82 |
Regents of the University of Minnesota | 2620 |
80 |
Dana-Farber Cancer Institute, Inc. | 2455 |
79 |
Other owners | 8221 |